GLUT1 inhibition by BAY-876 induces metabolic changes and cell death in human colorectal cancer cells.

ABSTRACT:

Background

Glucose transporter 1 (GLUT1) is known to play a crucial role in glucose uptake in malignant tumors. GLUT1 inhibitors reportedly exhibit anti-tumor effects by suppressing cancer cell proliferation. BAY-876, a selective GLUT1 inhibitor, has been shown to inhibit tumor growth in ovarian and breast cancers. In this study, we investigated the anti-proliferative effects of BAY-876 treatment in human colorectal cancer (CRC) cell lines.

Methods

We investigated the metabolic changes and effects on proliferation from BAY-876 treatment in HCT116, DLD1, COLO205, LoVo, and Caco-2 cells in vitro. Additionally, a mouse xenograft model was established using HCT116 cells to examine the tumor-inhibitory effects of BAY-876 treatment in vivo.

Results

BAY-876 treatment inhibit

SUBMITTER: Hayashi M 

PROVIDER: S-EPMC12004878 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature